These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27847671)

  • 1. Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients.
    Kurlawala Z; Vatsalya V
    J Addict; 2016; 2016():6028971. PubMed ID: 27847671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of Heavy Drinking Patterns and Depression Severity Predicts Efficacy of Quetiapine Fumarate XR in Lowering Alcohol Intake in Alcohol Use Disorder Patients.
    Vatsalya V; Kong M; Marsano LM; Kurlawala Z; Chandras KV; Schwandt ML; Ramchandani VA; McClain CJ
    Subst Abuse; 2020; 14():1178221820955185. PubMed ID: 32963470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients.
    Vatsalya V; Pandey A; Schwandt ML; Cave MC; Barve SS; Ramchandani VA; McClain CJ
    Clin Drug Investig; 2016 Nov; 36(11):935-944. PubMed ID: 27503091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
    Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
    Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quetiapine: a review of its use in the management of bipolar depression.
    Sanford M; Keating GM
    CNS Drugs; 2012 May; 26(5):435-60. PubMed ID: 22519923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients.
    Litten RZ; Fertig JB; Falk DE; Ryan ML; Mattson ME; Collins JF; Murtaugh C; Ciraulo D; Green AI; Johnson B; Pettinati H; Swift R; Afshar M; Brunette MF; Tiouririne NA; Kampman K; Stout R;
    Alcohol Clin Exp Res; 2012 Mar; 36(3):406-16. PubMed ID: 21950727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence.
    Brown ES; Davila D; Nakamura A; Carmody TJ; Rush AJ; Lo A; Holmes T; Adinoff B; Caetano R; Swann AC; Sunderajan P; Bret ME
    Alcohol Clin Exp Res; 2014 Jul; 38(7):2113-8. PubMed ID: 24976394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.
    Kanba S; Murasaki M; Koyama T; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
    BMC Psychiatry; 2019 Jun; 19(1):198. PubMed ID: 31242884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.
    Thase ME; Demyttenaere K; Earley WR; Gustafsson U; Udd M; Eriksson H
    Depress Anxiety; 2012 Jul; 29(7):574-86. PubMed ID: 22753280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.
    Montgomery SA; Altamura AC; Katila H; Datto C; Szamosi J; Eriksson H
    Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.
    Trivedi MH; Bandelow B; Demyttenaere K; Papakostas GI; Szamosi J; Earley W; Eriksson H
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1733-44. PubMed ID: 23673347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.
    Katila H; Mezhebovsky I; Mulroy A; Berggren L; Eriksson H; Earley W; Datto C
    Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
    Bauer M; Dell'osso L; Kasper S; Pitchot W; Dencker Vansvik E; Köhler J; Jørgensen L; Montgomery SA
    J Affect Disord; 2013 Oct; 151(1):209-19. PubMed ID: 23810357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial.
    Garriga M; Solé E; González-Pinto A; Selva-Vera G; Arranz B; Amann BL; Saiz-Ruiz J; Pérez-Blanco J; Vieta E
    Eur Neuropsychopharmacol; 2017 Oct; 27(10):959-969. PubMed ID: 28882405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression.
    Murasaki M; Koyama T; Kanba S; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
    Psychopharmacology (Berl); 2018 Oct; 235(10):2859-2869. PubMed ID: 30069587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.
    Cutler AJ; Montgomery SA; Feifel D; Lazarus A; Aström M; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):526-39. PubMed ID: 19358790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use.
    Gao K; Ganocy SJ; Conroy C; Brownrigg B; Serrano MB; Calabrese JR
    Psychopharmacology (Berl); 2017 Aug; 234(15):2233-2244. PubMed ID: 28536866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.